EWTX

Edgewise Therapeutics, Inc.

Latest Form 4:Sale$286KbyDonovan Joanne M. (CMO) · filed Aug 14, 2026

Edgewise Therapeutics, Inc. (EWTX) has 17 SEC Form 4 filings (59 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Aug 14, 2026.

The most active filer is CMO Donovan Joanne M. with 7 filings. Insiders have net sold $14.0M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:Kevin Koch
  • Employees:117
  • HQ:Boulder, CO, US
  • IPO:2021-03-26

Insider Buying

$199K

reported purchases (SEC code P)

Insider Selling

$19.5M

reported sales (SEC code S)

Unique Insiders

7

in the rolling window

Market Cap

$4.6B

latest known value

Source
Donovan Joanne M.First in 3 months
Sale$286KAug 14SEC ↗
Donovan Joanne M.First in 3 months
Sale$127KAug 14SEC ↗
Sale$258KAug 14SEC ↗
MOORE JOHN RFirst filing
Sale$220KAug 14SEC ↗
Derakhshan BehradFirst filing
Sale$223KAug 14SEC ↗
KOCH KEVINFirst filing
Sale$785KAug 14SEC ↗
Russell Alan JFirst in 8 months
Sale$7.9MJul 2SEC ↗
Sale$164KMay 5SEC ↗
Sale$1.9MMay 5SEC ↗
Sale$926KApr 2SEC ↗
Sale$685KMar 31SEC ↗
Donovan Joanne M.First filing
Sale$507KMar 30SEC ↗
Edris BadreddinFirst filing
Sale$3.4MJan 23SEC ↗
Russell Alan JFirst filing
Sale$2.1MNov 13SEC ↗
Fox Jonathan CFirst filing
Purchase$199KNov 13SEC ↗

Related companies

Edgewise Therapeutics, Inc. is in the Healthcare sector.